|
|
Article: Fate Therapeutics Announces Creation of Small Molecule Platform for Commercial Scale Reprogramming.
- Article from:
- Blood Weekly
- Article date:
- November 5, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Fate Therapeutics, Inc. announced the generation of human induced pluripotent stem cells (iPSCs) using a combination of small molecules that significantly improves the speed and efficiency of reprogramming. The discoveries, which were made by Sheng Ding, Ph.D., under a research collaboration between Fate Therapeutics and The Scripps Research Institute (TSRI), represent a more than 200 fold improvement in reprogramming efficiency and reduce the reprogramming period to two weeks as compared to methods using only the four reprogramming factors (Oct 3/4, Sox2, Klf4 and c-Myc). This latest advancement has broad implications for the creation of "pharmaceutical grade" iPSCs, ...
Related newspaper, magazine, and journal articles:
|
|
Article: Fate Therapeutics Further Expands Executive ...
Clinical Trials Week;
March 23, 2009 ;
700+ words
...Fate Therapeutics, Inc. announced the continued ... therapeutic purposes (see also Fate Therapeutics, Inc.). oKen Batchelor has ... Grayson, president and CEO of Fate Therapeutics. oCombining the CompanyEs unmatched ...
|
|